FGFR inhibitor
This page covers all FGFR inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting FGFR (Fibroblast Growth Factor Receptor), FGFR (fibroblast growth factor receptor), FGFR1, FGFR2, FGFR3, FGFR4.
Targets
FGFR (Fibroblast Growth Factor Receptor) · FGFR (fibroblast growth factor receptor) · FGFR1, FGFR2, FGFR3, FGFR4
Phase 3 pipeline (25)
- JAB-3312 · Allist Pharmaceuticals, Inc. · Oncology
JAB-3312 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling. - F2695 · Pierre Fabre Medicament · Oncology
F2695 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cancer cells. - ZL-1310 · Zai Lab (Shanghai) Co., Ltd. · Oncology
ZL-1310 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - TQB3616 capsules · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Oncology
TQB3616 is a small-molecule inhibitor that targets fibroblast growth factor receptor (FGFR) signaling pathways. - JAB-21822 · Allist Pharmaceuticals, Inc. · Oncology
JAB-21822 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. - BPI-7711 · Beta Pharma Shanghai · Oncology
BPI-7711 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HS-20089 · Hansoh BioMedical R&D Company · Oncology
HS-20089 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HGP0412 capsule · Hanmi Pharmaceutical Company Limited · Oncology
HGP0412 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HIP0612 · Hanmi Pharmaceutical Company Limited · Oncology
HIP0612 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HMPL-760 · Hutchmed · Oncology
HMPL-760 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - AK0529 · Shanghai Ark Biopharmaceutical Co., Ltd. · Oncology
AK0529 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - SYR-472 · Takeda · Oncology
SYR-472 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. - HSK31858, tablet · Haisco Pharmaceutical Group Co., Ltd. · Oncology
HSK31858 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - JR-131 · Kissei Pharmaceutical Co., Ltd. · Oncology
JR-131 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to treat FGFR-driven cancers. - HSK39297 · Haisco Pharmaceutical Group Co., Ltd. · Oncology
HSK39297 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HS-20093 · Hansoh BioMedical R&D Company · Oncology
HS-20093 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - CBL-514 · Caliway Biopharmaceuticals Co., Ltd. · Oncology
CBL-514 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling. - HS-20137 · Hansoh BioMedical R&D Company · Oncology
HS-20137 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - BPI-16350 · Betta Pharmaceuticals Co., Ltd. · Oncology
BPI-16350 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - RAY1225 · Guangdong Raynovent Biotech Co., Ltd · Oncology
RAY1225 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling pathways. - HMPL-306 · Hutchison Medipharma Limited · Oncology
HMPL-306 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - BAY2927088 · Bayer · Oncology
BAY2927088 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to inhibit tumor cell proliferation and survival. - HS-10296 · Jiangsu Hansoh Pharmaceutical Co., Ltd. · Oncology
HS-10296 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HS-10234 · Jiangsu Hansoh Pharmaceutical Co., Ltd. · Oncology
HS-10234 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - TAS-120 · Taiho Oncology, Inc. · Oncology
TAS-120 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to suppress tumor cell growth.
Phase 2 pipeline (4)
- AFX3772 · GlaxoSmithKline · Oncology
AFX3772 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. - E7337 · Eisai Inc. · Oncology
E7337 is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) signaling. - LY4065967 · Eli Lilly and Company · Oncology
LY4065967 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. - Erdafitinib monotherapy · Spanish Oncology Genito-Urinary Group · Oncology
Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling in cancer cells.